Moderna (MRNA) Change in Account Payables (2018 - 2026)

Moderna has reported Change in Account Payables for 9 years, with the latest figure at -$8.0 million in Q2 2026.

• Change in Account Payables for Q2 2026 came in at -$8.0 million, up 82.98% year-over-year; the trailing twelve-month figure through Jun 2026 was -$17.0 million (up 76.71% YoY), and the FY2025 annual result was -$92.0 million, down 33.33% from the prior year.
• Change in Account Payables grew to -$8.0 million in Q2 2026, from -$120.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $179.0 million in Q3 2023 and troughed at -$303.0 million in Q1 2024.
• A 5-year average of -$2.0 million and a median of $6.5 million in 2023 frame the typical range for Change in Account Payables.
• The widest annual swing landed in 2022, when Change in Account Payables jumped 905.56%; it then tumbled 234.29% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $151.0 million in 2022, then sank by 86.09% to $21.0 million in 2023, then jumped by 61.9% to $34.0 million in 2024, then sank by 35.29% to $22.0 million in 2025, then tumbled by 136.36% to -$8.0 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$8.0 million in Q2 2026, -$120.0 million in Q1 2026, and $22.0 million in Q4 2025.